S&P 500   4,305.00 (+0.18%)
DOW   34,146.05 (+0.69%)
QQQ   332.12 (-0.28%)
AAPL   172.63 (-0.32%)
MSFT   292.80 (-0.23%)
META   179.38 (-0.83%)
GOOGL   121.63 (-0.37%)
AMZN   144.72 (+1.08%)
TSLA   919.97 (-0.86%)
NVDA   188.71 (-0.85%)
NIO   20.88 (-1.97%)
BABA   92.80 (-1.49%)
AMD   100.21 (-0.79%)
MU   63.82 (-1.36%)
T   18.61 (+1.20%)
CGC   3.79 (-0.79%)
F   16.46 (+0.86%)
GE   81.03 (+1.53%)
DIS   125.36 (+0.89%)
AMC   24.47 (+1.07%)
PYPL   102.46 (+0.94%)
PFE   49.82 (+0.14%)
NFLX   246.72 (-0.96%)
S&P 500   4,305.00 (+0.18%)
DOW   34,146.05 (+0.69%)
QQQ   332.12 (-0.28%)
AAPL   172.63 (-0.32%)
MSFT   292.80 (-0.23%)
META   179.38 (-0.83%)
GOOGL   121.63 (-0.37%)
AMZN   144.72 (+1.08%)
TSLA   919.97 (-0.86%)
NVDA   188.71 (-0.85%)
NIO   20.88 (-1.97%)
BABA   92.80 (-1.49%)
AMD   100.21 (-0.79%)
MU   63.82 (-1.36%)
T   18.61 (+1.20%)
CGC   3.79 (-0.79%)
F   16.46 (+0.86%)
GE   81.03 (+1.53%)
DIS   125.36 (+0.89%)
AMC   24.47 (+1.07%)
PYPL   102.46 (+0.94%)
PFE   49.82 (+0.14%)
NFLX   246.72 (-0.96%)
S&P 500   4,305.00 (+0.18%)
DOW   34,146.05 (+0.69%)
QQQ   332.12 (-0.28%)
AAPL   172.63 (-0.32%)
MSFT   292.80 (-0.23%)
META   179.38 (-0.83%)
GOOGL   121.63 (-0.37%)
AMZN   144.72 (+1.08%)
TSLA   919.97 (-0.86%)
NVDA   188.71 (-0.85%)
NIO   20.88 (-1.97%)
BABA   92.80 (-1.49%)
AMD   100.21 (-0.79%)
MU   63.82 (-1.36%)
T   18.61 (+1.20%)
CGC   3.79 (-0.79%)
F   16.46 (+0.86%)
GE   81.03 (+1.53%)
DIS   125.36 (+0.89%)
AMC   24.47 (+1.07%)
PYPL   102.46 (+0.94%)
PFE   49.82 (+0.14%)
NFLX   246.72 (-0.96%)
S&P 500   4,305.00 (+0.18%)
DOW   34,146.05 (+0.69%)
QQQ   332.12 (-0.28%)
AAPL   172.63 (-0.32%)
MSFT   292.80 (-0.23%)
META   179.38 (-0.83%)
GOOGL   121.63 (-0.37%)
AMZN   144.72 (+1.08%)
TSLA   919.97 (-0.86%)
NVDA   188.71 (-0.85%)
NIO   20.88 (-1.97%)
BABA   92.80 (-1.49%)
AMD   100.21 (-0.79%)
MU   63.82 (-1.36%)
T   18.61 (+1.20%)
CGC   3.79 (-0.79%)
F   16.46 (+0.86%)
GE   81.03 (+1.53%)
DIS   125.36 (+0.89%)
AMC   24.47 (+1.07%)
PYPL   102.46 (+0.94%)
PFE   49.82 (+0.14%)
NFLX   246.72 (-0.96%)
NASDAQ:SGEN

Seagen - SGEN Stock Forecast, Price & News

$170.51
+1.98 (+1.17%)
(As of 08/16/2022 03:28 PM ET)
Add
Compare
Today's Range
$167.79
$172.53
50-Day Range
$139.40
$180.11
52-Week Range
$105.43
$192.79
Volume
51,761 shs
Average Volume
959,448 shs
Market Capitalization
$31.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$179.64

Seagen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
5.4% Upside
$179.79 Price Target
Short Interest
Healthy
1.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.48
Upright™ Environmental Score
News Sentiment
-0.19mentions of Seagen in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$8.07 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.42) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

660th out of 1,124 stocks

Biological Products, Except Diagnostic Industry

102nd out of 176 stocks

SGEN stock logo

About Seagen (NASDAQ:SGEN) Stock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Seagen Price Performance

Shares of NASDAQ:SGEN traded up $1.98 during trading hours on Tuesday, hitting $170.51. 44,635 shares of the company's stock traded hands, compared to its average volume of 959,448. Seagen has a 1 year low of $105.43 and a 1 year high of $192.79. The business has a fifty day moving average price of $170.09 and a 200-day moving average price of $148.32. The firm has a market capitalization of $31.45 billion, a P/E ratio of -41.82 and a beta of 0.57.

Seagen (NASDAQ:SGEN - Get Rating) last announced its earnings results on Thursday, July 28th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.09. The business had revenue of $497.50 million during the quarter, compared to analyst estimates of $437.77 million. Seagen had a negative return on equity of 24.33% and a negative net margin of 41.61%. The company's revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.47) earnings per share. As a group, equities analysts predict that Seagen will post -3.42 earnings per share for the current year.

Analysts Set New Price Targets

SGEN has been the topic of several analyst reports. BMO Capital Markets initiated coverage on Seagen in a research report on Thursday, June 23rd. They set a "market perform" rating and a $169.00 target price on the stock. SVB Leerink decreased their price target on Seagen from $159.00 to $152.00 and set an "outperform" rating on the stock in a report on Monday. TheStreet raised Seagen from a "d+" rating to a "c" rating in a report on Wednesday, July 6th. Oppenheimer raised their price target on Seagen from $160.00 to $208.00 and gave the company an "outperform" rating in a report on Tuesday, June 21st. Finally, JMP Securities lifted their target price on Seagen from $157.00 to $196.00 and gave the stock a "market outperform" rating in a report on Friday, July 8th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Seagen has a consensus rating of "Moderate Buy" and a consensus price target of $179.79.

Insider Buying and Selling

In related news, EVP Charles R. Romp sold 712 shares of the business's stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $179.46, for a total value of $127,775.52. Following the completion of the transaction, the executive vice president now owns 48,771 shares of the company's stock, valued at $8,752,443.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Charles R. Romp sold 712 shares of the business's stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $179.46, for a total value of $127,775.52. Following the completion of the transaction, the executive vice president now owns 48,771 shares of the company's stock, valued at $8,752,443.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Roger D. Dansey sold 34,635 shares of the company's stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $180.00, for a total value of $6,234,300.00. Following the transaction, the insider now directly owns 62,084 shares in the company, valued at $11,175,120. The disclosure for this sale can be found here. Insiders sold 47,347 shares of company stock valued at $8,029,876 over the last 90 days. Corporate insiders own 27.30% of the company's stock.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Stock News Headlines

Seagen (NASDAQ:SGEN) Upgraded by StockNews.com to "Buy"
Short Interest in Seagen Inc. (NASDAQ:SGEN) Decreases By 15.3%
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Company Calendar

Last Earnings
7/28/2022
Today
8/16/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
2,675
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$179.79
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$145.00
Forecasted Upside/Downside
+5.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Net Income
$-674,470,000.00
Pretax Margin
-41.60%

Debt

Sales & Book Value

Annual Sales
$1.57 billion
Book Value
$16.76 per share

Miscellaneous

Free Float
134,084,000
Market Cap
$31.45 billion
Optionable
Optionable
Beta
0.57

Social Links















SGEN Stock - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGEN shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price forecast for 2022?

12 equities research analysts have issued 1 year target prices for Seagen's shares. Their SGEN share price forecasts range from $145.00 to $220.00. On average, they predict the company's share price to reach $179.14 in the next year. This suggests a possible upside of 6.3% from the stock's current price.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How have SGEN shares performed in 2022?

Seagen's stock was trading at $154.60 at the start of the year. Since then, SGEN shares have increased by 9.0% and is now trading at $168.53.
View the best growth stocks for 2022 here
.

When is Seagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our SGEN earnings forecast
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings results on Thursday, July, 28th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.09. The biotechnology company had revenue of $497.50 million for the quarter, compared to the consensus estimate of $437.77 million. Seagen had a negative trailing twelve-month return on equity of 24.33% and a negative net margin of 41.61%. Seagen's revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.47) EPS.

What guidance has Seagen issued on next quarter's earnings?

Seagen updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.71 billion-$1.79 billion, compared to the consensus revenue estimate of $1.78 billion.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (2.49%), State Street Corp (1.87%), FMR LLC (1.45%), Franklin Resources Inc. (0.79%), Pictet Asset Management SA (0.59%) and Macquarie Group Ltd. (0.53%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Lip Bu Tan, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

How do I buy shares of Seagen?

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $168.53.

How much money does Seagen make?

Seagen (NASDAQ:SGEN) has a market capitalization of $31.08 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674,470,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis.

How many employees does Seagen have?

The company employs 2,675 workers across the globe.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
When was Seagen founded?

Seagen was founded in 1998.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.